Alliance for Pandemic Preparedness

January 13, 2021

Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-through Community Testing Site in Massachusetts

Category:

Topic:

Keywords (Tags): ,

[Pre-print, not peer-reviewed] An evaluation of the Abbott BinaxNOW COVID-19 Ag Card in a drive-through community testing site in Massachusetts using anterior nasal swab RT-PCR for clinical testing found that BinaxNOW had very high specificity in both adults and children (100% for both) and very high sensitivity in newly symptomatic adults (96.5% within 7 days of symptoms). Sensitivity and specificity in asymptomatic adults were 70.2% and 99.6%, respectively, and in asymptomatic children were 65.4% and 99.0%, respectively. Overall, 95.8% sensitivity was observed with Ct ≤30.

Pollock et al. (Jan 12, 2021). Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-through Community Testing Site in Massachusetts. Pre-print downloaded Jan 13 from https://www.medrxiv.org/content/10.1101/2021.01.09.21249499v1